🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Italy / NCT06775028
Recruiting Not applicable

Integrated Approach in Frail Older People with Atrial Fibrillation

NCT06775028 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-04-11
Last updated
2025-01-14

Condition(s) studied

Atrial Fibrillation (AF)HypertensionCoronary Arterial Disease (CAD)Heart FailureCOPDPeripheral Arterial DiseaseCKDDiabetes MellitusStrokeTIA (Transient Ischemic Attack)

Investigational drug(s) / intervention(s)

iABC platform use

iABC platform use: The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.

Study summary

The study will verify if a structured multidisciplinary approach (called iABC), aimed to improve the appropriate management of elderly AF patients with multimorbidity (the i-ABC group), would provide a clear evidence of an improvement in clinical conditions and quality of life compared to usual clinical care. The i-ABC group in AFFIRMO will follow the ABC pathway, focused on three domains: avoid stroke with anticoagulation (with optimized VKA or label-adherent DOAC use); better symptom management; and optimized management of associated cardiovascular and non cardiovascular comorbidities.

The study will be conducted in Bulgaria, Denmark, Italy, Romania, Serbia and Spain .

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Outpatients of both sexes with age ≥65 years; * First diagnosed, paroxysmal, persistent, long-standing persistent or permanent AF, confirmed as per guideline-recommended diagnostic criteria for AF, e.g. with electrocardiogram (ECG) or Holter monitoring; * ≥1 additional long-term comorbidity, thus fulfilling the definition of multimorbidity: hypertension (treated with at least 2 antihypertensive drugs), coronary artery disease (CAD), peripheral artery disease, heart failure, stroke/TIA, diabetes mellitus, COPD, CKD. Exclusion Criteria: * Mechanical prosthetic heart valve or moderate/severe mitral stenosis; * Patient unwilling to be enrolled and sign written informed consent; * Patient unable to understand the study and attend the follow-up; * Serious diseases with a life expectancy inferior to 12 months; * Patients included in other interventional studies. Only for sites randomized to the iABC group: \- Patient without a device suitable for iABC use.

Primary outcome measure(s)

Trial sites (50)

FacilityCityRegionStatus
MHAT Haskovo AD-Cardiology Haskovo Bulgaria Recruiting
SHATS Sveti Georgi - Pernik-Cardiology Pernik Bulgaria Recruiting
MBAL Sv. Ivan Rilski-Cardiology Plovdiv Bulgaria Recruiting
UMBAL Sveti Georgi EAD-Clinic of Cardiology Plovdiv Bulgaria Recruiting
UMHAT Pulmed Plovdiv-Cardiology Plovdiv Bulgaria Recruiting
Acibadem City Clinic Tokuda Hospital-Dept of Electrophysiology Clinic of Cardiology Sofia Bulgaria Recruiting
Acibadem City Clinic UMBAL Cardiovascular Center-CARDIOLOGY Sofia Bulgaria Recruiting
National Heart Hospital-ICCU Sofia Bulgaria Recruiting
Herlev Hospital-Department of Cardiology Herlev Denmark Recruiting
North Denmark Regional Hospital-Department of Cardiology Hjørring Denmark Recruiting
Horsens Regional Hospital-Department of Medicine Horsens Denmark Recruiting
Silkeborg Regional Hospital-Diagnostic Centre, University Clinic for Development of Innovative Patient Pathways Silkeborg Denmark Recruiting
Azienda Ospedaliera S. Anna E S. Sebastiano-Cardiologia Clinica Universitaria Caserta CE Recruiting
Ospedale Santa Maria Nuova-Cardiologia - Firenze 1 Florence FI Recruiting
Als Genovese Palazzo Della Salute-Cardiologia Quarto Genova GE Recruiting
Ospedale Della Misericordia-U.O. Di Cardiologia Grosseto GR Recruiting
Fondazione Irccs San Gerardo Dei Tintori - Ospedale San Gerardo - U.O.C. Cardiologia Monza MB Recruiting
Istituti Clinici Scientifici Maugeri Irccs Sede Di Milano-Uo Cure Subacute Milan MI Recruiting
Ospedale Civile 'Guglielmo Da Saliceto'-Uoc Cardiologia E Utic Piacenza PC Recruiting
Ospedale Gubbio-Gualdo Tadino-U.O. Di Utic E Cardiologia Gubbio PG Recruiting
Policlinico Umberto Primo-Medicina Interna E Immunologia Clinica Roma RM Recruiting
Azienda Ospedaliera Santa Maria-Medicina Interna Terni TR Recruiting
Pou "Santa Maria Della Misericordia"-S.O.C. Cardiologia Udine UD Recruiting
Aou Federico Ii-Medicina Metabolico-Riabilitativa Naples Italy Recruiting
Spitalul Clinic Colentina-Cardiology Bucharest Romania Recruiting
Spitalul Clinic Colentina-Internal Medicine Bucharest Romania Recruiting
Spitalul Clinic Coltea-Internal Medicine and Cardiology Bucharest Romania Recruiting
Spitalul Clinic de Urgenta 'Bagdasar-Arseni'-Cardiology Bucharest Romania Recruiting
Spitalul Clinic de Urgenta Bucuresti-Cardiology Bucharest Romania Recruiting
Spitalul Clinic Prof.Dr.Th.Burghele-Internal Medicine and Cardiology Bucharest Romania Recruiting
Spitalul Universitar de Urgenta Elias-Cardiology Bucharest Romania Recruiting
Spitalul Universitar de Urgenta Militar Central Dr. Carol Davila-Cardiac Function Laboratory Bucharest Romania Recruiting
Institute for Cardiovascular Diseases Dedinje-Pacemaker and electrophysiology department Belgrade Serbia Recruiting
KBC Bezanijska Kosa-Cardiology Department Belgrade Serbia Recruiting
KBC Zemun-Cardiology Department Belgrade Serbia Recruiting
University Clinical Centre of Serbia-Department for cardiac arrhythmias Belgrade Serbia Recruiting
University Clinical Centre of Serbia-Department for invasive electrophysiology Belgrade Serbia Recruiting
University Clinical Centre of Serbia-Emergency centre Belgrade Serbia Recruiting
University Clinical Centre of Kragujevac-Cardiology Department Kragujevac Serbia Recruiting
University Clinical Centre of Nis-Cardiology Department Niš Serbia Recruiting

+ 10 more sites — see the full list on the official registry below.

More Heart Care Foundation trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06775028 on ClinicalTrials.gov ↗ ← All trials in Italy